Investigating how a specific signaling pathway affects the risk of developing osteoarthritis.
Contribution of the NOD/RIPK2 signaling pathway to osteoarthritis susceptibility
This study is looking at how certain genes might make people more likely to develop osteoarthritis, and by using animal models, researchers hope to find new ways to treat this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-11058416 on NIH RePORTER |
What this research studies
This research focuses on understanding the NOD/RIPK2 signaling pathway and its role in making individuals more susceptible to osteoarthritis (OA). By analyzing genetic information from families with inherited OA, the researchers aim to identify specific genetic variations that contribute to the disease. The study involves using animal models to observe how these genetic changes affect joint health and inflammation. Ultimately, the goal is to uncover potential therapeutic targets that could lead to new treatments for OA.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with a family history of osteoarthritis or those experiencing early signs of joint degeneration.
Not a fit: Patients with osteoarthritis not linked to genetic factors or those with advanced OA may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new therapies that modify the course of osteoarthritis, improving joint health and quality of life for patients.
How similar studies have performed: Previous research has shown promising results in targeting similar signaling pathways for other inflammatory conditions, suggesting potential for success in this area as well.
Where this research is happening
Salt Lake City, United States
- University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Jurynec, Michael J — University of Utah
- Study coordinator: Jurynec, Michael J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.